The terms and processes by which investigative sites are paid to conduct clinical trials have long been a thorny issue. These issues have impacted clinical research sites’ ability to focus on conducting quality research and meet enrollment goals — as well as continue their role as the bridge from promise to reality for new therapeutic treatments.
Following a successful evaluation of Clinithink, Ltd.’s CLiX ENRICH for Clinical Trials solution at the Icahn School of Medicine at Mount Sinai (ISMMS), Mount Sinai has signed an agreement with the company to deploy the solution across the organization to accelerate patient recruitment for clinical trials, as well as to support its personalized medicine initiatives.
CLiX ENRICH will help to streamline the patient pre-screening process at Mount Sinai by processing large volumes of progress notes and reports from electronic health records and flagging patients whose clinical documentation indicates they closely match a trial’s inclusion/exclusion criteria. The result is an ENRICHed List, a prioritized shortlist of highly eligible patients. This will allow investigators to be much quicker in selecting patients to approach for consent and screening. The solution removes the need for extensive manual chart reviews almost entirely, releasing valuable time traditionally spent by site investigators and coordinators on this laborious task.